Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$987.52
-0.1%
$946.66
$623.78
$1,133.95
$929.98B0.483.20 million shs3.74 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.51
+0.2%
$27.17
$21.97
$28.75
$150.74B0.3542.89 million shs40.14 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$1.44
+2.1%
$2.33
$0.13
$1.04
$27.73M1.581.05 million shs44,057 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+2.47%+13.14%+5.68%-10.67%+20.37%
Pfizer Inc. stock logo
PFE
Pfizer
+0.29%-0.09%-6.85%-1.52%+10.73%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-3.42%+5.22%-33.18%-51.88%-71.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$987.52
-0.1%
$946.66
$623.78
$1,133.95
$929.98B0.483.20 million shs3.74 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.51
+0.2%
$27.17
$21.97
$28.75
$150.74B0.3542.89 million shs40.14 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$1.44
+2.1%
$2.33
$0.13
$1.04
$27.73M1.581.05 million shs44,057 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+2.47%+13.14%+5.68%-10.67%+20.37%
Pfizer Inc. stock logo
PFE
Pfizer
+0.29%-0.09%-6.85%-1.52%+10.73%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-3.42%+5.22%-33.18%-51.88%-71.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,217.5923.30% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.748.40% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VIRI, LLY, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Lower Price TargetBuy$1,294.00 ➝ $1,133.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,205.00 ➝ $1,230.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,260.00 ➝ $1,283.00
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
4/27/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Lower Price TargetOutperform$1,296.00 ➝ $1,058.00
4/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,163.00 ➝ $1,183.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B14.27$25.64 per share38.51$33.13 per share29.81
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.41$4.43 per share5.98$15.26 per share1.74
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1535.0822.971.0734.98%105.77%23.76%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.499.40N/A12.42%20.48%8.86%N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/A

Latest VIRI, LLY, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.70%+15.18%24.58%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.49%-13.20%131.30%16 Years
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A

Latest VIRI, LLY, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.42%5/8/20265/8/20266/12/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.72%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.16
0.87
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million943.50 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.69 billion5.65 billionOptionable
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionNo Data

Recent News About These Companies

Virios Therapeutics (NASDAQ:VIRI) Trading Down 3.4% - What's Next?
Dogwood Therapeutics Inc (DWTX)
Dogwood prices 578,950 shares at $8.26 in registered direct offering
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
Dogwood announces first patient dosed in Phase 2b trial on Halneuron
Dogwood Therapeutics faces potential Nasdaq delisting
Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue
DWTX: Phase 2 Long COVID Results Expected Soon
Dogwood Therapeutics Reports Q3 2024 Financial Results
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$987.52 -1.35 (-0.14%)
Closing price 03:59 PM Eastern
Extended Trading
$984.48 -3.04 (-0.31%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer stock logo

Pfizer NYSE:PFE

$26.51 +0.06 (+0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$26.46 -0.06 (-0.21%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$1.44 +0.03 (+2.13%)
As of 05/5/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.